CN105687962A - 治疗冠状动脉粥样硬化的冲剂及制备方法 - Google Patents
治疗冠状动脉粥样硬化的冲剂及制备方法 Download PDFInfo
- Publication number
- CN105687962A CN105687962A CN201610164887.7A CN201610164887A CN105687962A CN 105687962 A CN105687962 A CN 105687962A CN 201610164887 A CN201610164887 A CN 201610164887A CN 105687962 A CN105687962 A CN 105687962A
- Authority
- CN
- China
- Prior art keywords
- parts
- electuary
- preparation
- weight
- hour
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 201000001320 Atherosclerosis Diseases 0.000 title abstract description 13
- 210000004351 coronary vessel Anatomy 0.000 title abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 52
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 36
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 claims description 32
- 208000026758 coronary atherosclerosis Diseases 0.000 claims description 32
- 229940079593 drug Drugs 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 238000001704 evaporation Methods 0.000 claims description 21
- 230000008020 evaporation Effects 0.000 claims description 21
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 21
- 239000010409 thin film Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 230000001376 precipitating effect Effects 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 14
- 235000003935 Hippophae Nutrition 0.000 claims description 13
- 241000229143 Hippophae Species 0.000 claims description 13
- 241000237524 Mytilus Species 0.000 claims description 10
- 241000222640 Polyporus Species 0.000 claims description 10
- 239000004375 Dextrin Substances 0.000 claims description 9
- 229920001353 Dextrin Polymers 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 9
- 235000019425 dextrin Nutrition 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 7
- 230000003179 granulation Effects 0.000 claims description 7
- 238000005469 granulation Methods 0.000 claims description 7
- 230000005484 gravity Effects 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 19
- 239000008280 blood Substances 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 11
- 208000002193 Pain Diseases 0.000 abstract description 8
- 230000006870 function Effects 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 4
- 230000003213 activating effect Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 244000296912 Ageratum conyzoides Species 0.000 abstract 1
- 241000304531 Allium macrostemon Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 241000222684 Grifola Species 0.000 abstract 1
- 240000000950 Hippophae rhamnoides Species 0.000 abstract 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 241000237536 Mytilus edulis Species 0.000 abstract 1
- 241001522129 Pinellia Species 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 240000006023 Trichosanthes kirilowii Species 0.000 abstract 1
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 abstract 1
- 241000301400 Trogopterus Species 0.000 abstract 1
- 230000000364 effect on atherosclerosis Effects 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 210000003608 fece Anatomy 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 230000005906 menstruation Effects 0.000 abstract 1
- 230000003340 mental effect Effects 0.000 abstract 1
- 235000020638 mussel Nutrition 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 description 18
- 102000007330 LDL Lipoproteins Human genes 0.000 description 16
- 108010007622 LDL Lipoproteins Proteins 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 15
- 206010062717 Increased upper airway secretion Diseases 0.000 description 12
- 208000026435 phlegm Diseases 0.000 description 12
- 210000000038 chest Anatomy 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 206010047700 Vomiting Diseases 0.000 description 8
- 206010025482 malaise Diseases 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 208000007536 Thrombosis Diseases 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- 210000000497 foam cell Anatomy 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 4
- 206010008479 Chest Pain Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000003143 atherosclerotic effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 206010000077 Abdominal mass Diseases 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000003014 Bites and Stings Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 206010018498 Goitre Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 206010033078 Otitis media Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 241000517307 Pediculus humanus Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000036523 atherogenesis Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 201000003872 goiter Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 208000009084 Cold Injury Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 208000014770 Foot disease Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000018779 Globus Sensation Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 244000208734 Pisonia aculeata Species 0.000 description 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 1
- 235000010829 Prunus spinosa Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010062104 Renal mass Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 230000002595 cold damage Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- -1 compound saccharide Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- FPVGTPBMTFTMRT-NSKUCRDLSA-L fast yellow Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(N)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 FPVGTPBMTFTMRT-NSKUCRDLSA-L 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004220 fundus oculi Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 208000010540 rapid respiration Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/904—Stemonaceae (Stemona family), e.g. croomia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了治疗冠状动脉粥样硬化的冲剂及制备方法,主要由下列原料药制备而成,均为重量份:瓜蒌6-9,胜红蓟6-12,桂枝6-10,沙棘2-8,薤白6-15,桑皮3-6,丹参4-9,淡菜5-9,百部2-5,半夏6-15,猪苓6-12,泽泻4-10,五灵脂3-9。本发明的优良效果还表现在:所选材料皆为传统中药材料,无任何毒副作用;本组方完全符合中医药原则和冠心病患者身心特点,在总原则的前提下,可根据不同人群有不同组方,功能不同,本发明冲剂具有活血通经,散淤止痛功效,对治疗动脉粥样硬化与冠心病有特殊的疗效。
Description
分案申请,原申请号2014100821592,申请日2014.03.07,名称治疗冠状动脉粥样硬化的冲剂及制备方法。
技术领域
本发明涉及中医中药领域,特别是涉及一种治疗治疗冠状动脉粥样硬化的冲剂及其制备方法。
背景技术
动脉粥样硬化(Atherosclerosis)是动脉硬化中最常见而重要的类型,其特点是受累动脉的内膜有类脂质的沉着,复合糖类的积聚,继而纤维组织增生和钙沉着,并有动脉中层的病变。本病主要累及大型及中型的肌弹力型动脉,以主动脉、冠状动脉及脑动脉为多见,常导致管腔闭塞或管壁破裂出血等严重后果。发生在冠状动脉上的动脉粥样硬化称为冠状动脉粥样硬化(CoronaryAtherosclerotic)。它是最常见的狭窄性冠状动脉疾病,特别是肌壁外冠状动脉支的动脉粥样硬化。冠状动脉近侧段之所以好发动脉粥样硬化是由于它比所有器官动脉都靠近心室,因而承受最大的收缩压撞击。再者,冠状动脉血管树由于心脏的形状而有多数方向改变,因此亦承受较大的血流剪应力。
好发部位:据我国的尸检统计资料,病变的总检出率、狭窄检出率和平均级别均以前降支最高,其余依次为右主干、左主干或左旋支、后降支。性别差异:20~50岁病变检出率,男性显著高于女性;60岁以后男女无明显差异。
动脉粥样硬化是导致一系列心、脑血管病的基础,以下我们就来简单的讲述一下动脉粥样硬化形成的机理。氧化的低密度脂蛋白(Ox-LDL)是动脉粥样硬化的核心,当血液中的低密度脂蛋白(LDL)被活性氧(ROS)等自由基氧化后叫着“氧化的低密度脂蛋白”简称“Ox-LDL”,他就会进入血管壁,1.Ox-LDL损坏血管壁的内皮细胞,并且让内皮细胞间隙变大;2.Ox-LDL刺激单核细胞游走进入血管壁;3.OX-LDL被巨噬细胞以及血管的平滑肌细胞的受体所吞噬,----形成泡沫细胞,4.Ox-LDL使上述两种泡沫细胞坏死崩解,形成糜粥样坏死物,粥样硬化斑块形成。
这里要特别强调的是氧化的低密度脂蛋白(Ox-LDL)在整个动脉粥样硬化形成过程中起了核心作用,而不是我们老百姓一般认为的“低密度脂蛋白”或者“血脂”或者“胆固醇”概念,如果LDL不被氧化为Ox-LDL,机体的单核细胞认为LDL是“自己人”,不会对他(LDL)进行吞噬并形成泡沫细胞,只有当他(LDL)被氧化成Ox-LDL后,才被机体的单核细胞等炎症介质认为是【异己】成分,并对之进行吞噬,消灭,最终形成泡沫细胞。因此防止LDL氧化为Ox-LDL是遏制动脉粥样硬化的关键所在,而不是我们常规理解的降低胆固醇、降低血脂、降低低密度脂蛋白(LDL)等。
动脉粥样硬化后的血管,血栓的形成是一个比较复杂的炎症过程。随着上述动脉粥样硬化斑块的生长,常常是导致上述泡沫细胞死亡,形成坏死性核心,他能与持续存在的炎症反应,使上述粥样硬化斑块变得很不稳定,活化的巨噬细胞分泌一种酶降解胶原纤维帽,不稳定斑块形成,这样就很容易破裂。破裂后的斑块大量高度致凝血的物质释放入血管腔,导致局部血栓形成。当这种血栓形成在脑部的血管,则叫脑血栓(脑梗塞、脑梗死),当脑血管处在一个薄弱的部位而且伴有高血压之类,或者斑块向血管外破裂就形成了脑出血,这两类情况中医叫中风、西医叫卒中;当这种血栓形成在心脏的冠状动脉,就叫心肌梗死(心肌梗塞);当这种血栓形成发生在眼底动脉,则就是黄斑变性。当这种血栓的形成出现在下肢动脉的时候,就导致像糖尿病的病足之类的改变。
申请公布号CN102973786A(申请号201210441546.1)的中国专利文献公开了一种治疗冠状动脉粥样硬化性心脏病的中药,由下述重量份的原料药制成:当归6-10份,三七3-5份,玄参6-8份,金银花12-15份,白薇5-9份,灵芝14-18份,葶苈子10-13份、桑白皮8-10份、降香6-8份、延胡索10-12份、党参15-20份,甘草5-20份,麦冬15-20份,磁石20-25份。申请公布号CN103550624A(申请号201310524895.4)的中国专利文献公开了一种治疗动脉粥样硬化与冠状动脉粥样硬化的中药制剂,其主要原料及重量份分别是,当归30份、川穹15份、白芍18份、麦芽30份、红花12份、昆布12份、薄荷10份、牛舌草30份、芦根30份。
总之,中医药在治疗本病方面取得了较好的疗效,但还存在一些问题:临床上对防治冠状动脉粥样硬化还需同步研究,对治疗冠状动脉粥样硬化出现的不适症状疗效也有待于进一步提高。
发明内容
针对现有技术的不足,本发明的目的是提供一种制备简单、服用方便、便于携带、易久服的治疗冠状动脉粥样硬化的冲剂,该中药组合物疗效确切且无毒副作用。
本发明的技术方案是:
治疗冠状动脉粥样硬化的冲剂,主要由下列原料药制备而成,均为重量份:瓜蒌6-9,胜红蓟6-12,桂枝6-10,沙棘2-8,薤白6-15,桑皮3-6,丹参4-9,淡菜5-9,百部2-5,半夏6-15,猪苓6-12,泽泻4-10,五灵脂3-9。
前面所述的治疗冠状动脉粥样硬化的冲剂,优选的是,主要由下列原料药制备而成,均为重量份:瓜蒌7-8,胜红蓟8-10,桂枝7-9,沙棘4-6,薤白9-12,桑皮4-5,丹参6-8,淡菜6-8,百部3-4,半夏9-11,猪苓8-10,泽泻6-8,五灵脂5-7。
前面所述的治疗冠状动脉粥样硬化的冲剂,更佳优选的是,主要由下列原料药制备而成,均为重量份:瓜蒌7.5,胜红蓟9,桂枝8,沙棘5,薤白10,桑皮4.5,丹参7,淡菜7,百部3.5,半夏10,猪苓9,泽泻7,五灵脂6。
所述治疗冠状动脉粥样硬化的冲剂的制备方法是:
(1)将整理好的原料药混合煎汁,共煎三次,每次待水沸后,再煎0.8-1.4小时,过滤取汁,药汁合并,用薄膜蒸发至每毫升含生药1-3克,加入一倍重量的乙醇(95%)边加边搅拌,沉淀15-25小时后过滤;
(2)滤液用薄膜蒸发至每毫升药液相当4-5克生药,加入冷水稀释成每毫升含生药1-3克,沉淀8-24小时后过滤;
(3)滤液用薄膜蒸发至浸膏状,浓缩液比重控制为1.05-1.2:1,放冷至80℃以下称总固体量;
(4)加总固体量2-5倍重量的白砂糖,0.5-1.2倍重量的糊精(优选加入0.9倍重量的糊精),用乙醇(65%),调节干湿度,用颗粒机制成颗粒,包装。
上述冲剂的制备方法,优选的是,步骤(1)再煎1-1.3小时(优选1.2小时)。
上述冲剂的制备方法,优选的是,步骤(1)沉淀18-23小时后过滤(优选20小时)。
上述治疗冠状动脉粥样硬化的冲剂的制备方法,优选的是,步骤(2)蒸发至每毫升药液相当生药4.2-4.8克(优选4.5克)。
上述治疗冠状动脉粥样硬化的冲剂的制备方法,优选的是,步骤(2)沉淀13-18小时后过滤(优选15小时)。
上述治疗冠状动脉粥样硬化的冲剂的制备方法,优选的是,步骤(4)加总固体量3-4倍重量的白砂糖(优选3.5倍)。
本发明还提供了所述冲剂在制备治疗冠状动脉粥样硬化、心肌梗塞、心肌坏死、心绞痛的药物时的应用。
服用方法:为使本发明达到最佳效果,服用时,每次一袋,每天3次,温开水冲服,10天一个疗程。
本发明所用主要中药原料的药理如下:
瓜蒌:甘苦,寒。成无己:“味苦,寒。入肺、胃、大肠经。功能主治:润肺,化痰,散结,润肠。治痰热咳嗽,胸痹,结胸,肺痿咳血,消渴,黄疸,便秘,痈肿初起。
胜红蓟:辛、微苦,凉。功能主治:祛风清热,止痛,止血,排石。用于上呼吸道感染,扁桃体炎,咽喉炎,急性胃肠炎,胃痛,腹痛,崩漏,肾结石,膀胱结石;外用治湿疹,鹅口疮,痈疮肿毒,蜂窝织炎,下肢溃疡,中耳炎,外伤出血。
桂枝:性味:辛、甘,温。归经:归心、肺、膀胱经。功效:发汗解肌,温通经脉,助阳化气,平冲降气。主治:用于风寒感冒,脘腹冷痛,血寒经闭,关节痹痛,痰饮,水肿,心悸,奔豚。
沙棘:别名达尔、沙枣、醋柳果、大尔卜兴、醋柳、酸刺子、酸柳柳、其察日嘎纳、酸刺、黑刺、黄酸刺、酸刺刺,沙棘果和油具有很高的药用价值,可降低胆固醇,治愈心绞痛等作用,还有防治冠状动脉粥样硬化性心脏病的作用;有祛痰、止咳、平喘和治疗慢性气管炎的作用;能治疗胃和十二指肠溃疡以及消化不良等,对慢性浅表性胃炎、萎缩性胃炎、结肠炎等病症疗效显著;对烧伤、烫伤、刀烧、冻伤有很好的治疗作用;对妇女宫颈糜烂有良好的治疗效果。味酸;涩;性温,止咳化痰;健胃消食;活血散瘀。主咳嗽痰多;肺脓肿;消化不良;食积腹痛;胃痛;肠炎;闭经;跌打瘀肿。
薤白:性味:辛、苦,温。归经:归肺、胃、大肠经。功效:通阳散结,行气导滞。主治:用于胸痹疼痛,痰饮咳喘,泄痢后重。
桑皮:功用主治:肺热喘咳,水饮停肺,胀满喘急,尤善泻肺火而平喘咳,治肺热咳喘,痰稠而黄。药性:味甘、微苦、归肺、脾经。
丹参:性味:苦,微寒。归经:归心、肝经。功效:祛瘀止痛,活血通经,清心除烦。主治:用于月经不调,经闭痛经,癥瘕积聚,胸腹刺痛,热痹疼痛,疮疡肿痛,心烦不眠;肝脾肿大,心绞痛。
淡菜:咸,温。补肝肾,益精血,消瘿瘤。治虚劳羸瘦,眩晕,盗汗,阳痿,腰痛,吐血,崩漏,带下,瘿瘤,疝瘕。能补五脏,益阳事,理腰脚气,消宿食,除腹中冷气,痃癖。
百部:性味:甘、苦,微温。归经:归肺经。功效:润肺下气止咳,杀虫。主治:用于新久咳嗽,肺痨咳嗽,百日咳;外用于头虱,体虱,蛲虫病,阴痒。蜜百部润肺止咳。用于阴虚劳嗽。
半夏:其味辛,性温,有毒;归脾、胃、肺经,药用价值块茎入药,有毒,能燥湿化痰,降逆止呕,生用消疖肿;主治咳嗽痰多、恶心呕吐;外用治急性乳腺炎、急慢性化浓性中耳炎。功效主治:湿化痰,降逆止呕,消痞散结。治湿痰冷饮,呕吐,反胃,咳喘痰多,胸膈胀满,痰厥头痛,头晕不眠。外消痈肿。用于痰多咳喘、痰饮眩悸、内痰眩晕、呕吐反胃、胸脘痞闷、梅核气症;生用外治痈肿痰核。姜半夏多用于降逆止呕。
猪苓:性味:甘、淡,平。归经:归肾、膀胱经。功效:利水渗湿。主治:用于小便不利,水肿,泄泻,淋浊,带下。
泽泻:性味:甘,寒。归经:归肾、膀胱经。功效:利小便,清湿热。主治:用于小便不利.水肿胀满,泄泻尿少,痰饮眩晕,热淋涩痛;高血脂。
五灵脂:甘,温。活血散瘀,炒炭止血。用于心腹淤血作痛,痛经,血瘀经闭,产后淤血腹痛;炒炭治崩漏下血;外用治跌打损伤,蛇、虫咬伤。
本发明提供冲剂组方科学,各种剂型的制备方法简单,所得产品服用方便、便于携带。除此之外,本发明的优良效果还表现在:
1、所选材料皆为传统中药材料,无任何毒副作用;
2、本组方完全符合中医药原则和冠状动脉粥样硬化患者身心特点,在总原则的前提下,可根据不同人群有不同组方,功能不同。
3、药源易得,药材成本低廉,能够减轻患者负担。
具体实施方式
下面结合实施例和实验例详细说明本发明的技术方案,但保护范围不限于此。
实施例1治疗冠状动脉粥样硬化的冲剂,主要由下列原料药制备而成,均为重量份(每份取10g):瓜蒌6,胜红蓟6,桂枝6,沙棘2,薤白6,桑皮3,丹参4,淡菜5,百部2,半夏6,猪苓6,泽泻4,五灵脂3。
上述治疗冠状动脉粥样硬化的冲剂的制备方法,步骤是:
(1)将整理好的原料药混合煎汁,共煎三次,每次待水沸后,再煎0.8小时,过滤取汁,药汁合并,用薄膜蒸发至每毫升含生药1-3克,加入一倍重量的乙醇(95%)边加边搅拌,沉淀15小时后过滤;
(2)滤液用薄膜蒸发至每毫升药液相当4克生药,加入冷水稀释成每毫升含生药1-3克,沉淀8小时后过滤;
(3)滤液用薄膜蒸发至浸膏状,浓缩液比重控制为1.05-1.2:1,放冷至80℃以下称总固体量;
(4)加总固体量2倍重量的白砂糖,0.5倍重量的糊精,用乙醇(65%),调节干湿度,用颗粒机制成颗粒,包装。
典型病例一:张xx,男性,48岁。胸闷气短2年有余,每日晚上睡觉都感觉胸闷的很厉害,都无法正常的入眠,怕冷、心悸、四肢欠温暖,疲乏无力,腿肿腰酸,胸痛彻背等症。去医院检查,心脏彩超显示有回流,运动平板车显示为阳性,动脉造影显示为动脉硬化,医生给予服用本发明冲剂。
服用本实施例3所得冲剂,每次一袋,每天3次,温开水冲服,10天一个疗程。服用20天,胸闷,气短等症状明显减轻,疲乏无力亦减轻,纳量增,精神可,服用2个月,动脉造影显示为正常,继服4个月,不适症状消失,患者自感痊愈。
实施例2治疗冠状动脉粥样硬化的冲剂,主要由下列原料药制备而成,均为重量份(每份取15g):瓜蒌9,胜红蓟12,桂枝10,沙棘8,薤白15,桑皮6,丹参9,淡菜9,百部5,半夏15,猪苓12,泽泻10,五灵脂9。
上述治疗冠状动脉粥样硬化的冲剂的制备方法,步骤是:
(1)将整理好的原料药混合煎汁,共煎三次,每次待水沸后,再煎1.4小时,过滤取汁,药汁合并,用薄膜蒸发至每毫升含生药1-3克,加入一倍重量的乙醇(95%)边加边搅拌,沉淀25小时后过滤;
(2)滤液用薄膜蒸发至每毫升药液相当5克生药,加入冷水稀释成每毫升含生药1-3克,沉淀24小时后过滤;
(3)滤液用薄膜蒸发至浸膏状,浓缩液比重控制为1.05-1.2:1,放冷至80℃以下称总固体量;
(4)加总固体量5倍重量的白砂糖,1.2倍重量的糊精,用乙醇(65%),调节干湿度,用颗粒机制成颗粒,包装。
实施例3治疗冠状动脉粥样硬化的冲剂,主要由下列原料药制备而成,均为重量份(每份取25g):瓜蒌7,胜红蓟8,桂枝7,沙棘4,薤白9,桑皮4,丹参6,淡菜6,百部3,半夏9,猪苓8,泽泻6,五灵脂5。
上述治疗冠状动脉粥样硬化的冲剂的制备方法,步骤是:
(1)将整理好的原料药混合煎汁,共煎三次,每次待水沸后,再煎1小时,过滤取汁,药汁合并,用薄膜蒸发至每毫升含生药1-3克,加入一倍重量的乙醇(95%)边加边搅拌,沉淀18小时后过滤;
(2)滤液用薄膜蒸发至每毫升药液相当4.2克生药,加入冷水稀释成每毫升含生药1-3克,沉淀13小时后过滤;
(3)滤液用薄膜蒸发至浸膏状,浓缩液比重控制为1.05-1.2:1,放冷至80℃以下称总固体量;
(4)加总固体量3倍重量的白砂糖,0.8倍重量的糊精,用乙醇(65%),调节干湿度,用颗粒机制成颗粒,包装。
典型病例二:吕xx,年龄:46岁;性别:女性;主诉:间歇性胸痛胸闷3个月;现病史:患者6小时前出现无明显诱因胸痛,为胸骨后闷痛,呈持续性,伴后背部放射,无腹胀,无腹痛,无恶心呕吐,无畏寒发热,无咳嗽咳痰。讨论:心脏彩超显示有回流,运动平板车显示为阳性,动脉造影显示为动脉硬化。
服用本实施例3所得冲剂,每次一袋,每天3次,温开水冲服,10天一个疗程。服用20天,胸痛胸闷明显减轻,心中烦乱亦减轻,纳量增,精神可,服用1个月,症状消除,夜眠安,心烦除,力气增,纳食可,继服2个月,患者服用时未出现任何不适,患者自感痊愈。
实施例4治疗冠状动脉粥样硬化的冲剂,主要由下列原料药制备而成,均为重量份(每份取5g):瓜蒌8,胜红蓟10,桂枝9,沙棘6,薤白12,桑皮5,丹参8,淡菜8,百部4,半夏11,猪苓10,泽泻8,五灵脂7。
上述治疗冠状动脉粥样硬化的冲剂的制备方法,步骤是:
(1)将整理好的原料药混合煎汁,共煎三次,每次待水沸后,再煎1.3小时,过滤取汁,药汁合并,用薄膜蒸发至每毫升含生药1-3克,加入一倍重量的乙醇(95%)边加边搅拌,沉淀23小时后过滤;
(2)滤液用薄膜蒸发至每毫升药液相当4.8克生药,加入冷水稀释成每毫升含生药1-3克,沉淀18小时后过滤;
(3)滤液用薄膜蒸发至浸膏状,浓缩液比重控制为1.05-1.2:1,放冷至80℃以下称总固体量;
(4)加总固体量4倍重量的白砂糖,1倍重量的糊精,用乙醇(65%),调节干湿度,用颗粒机制成颗粒,包装。
典型病例三:黄xx,50岁,男,于某日出现较以往更剧烈而频繁的心绞痛,心绞痛持续时间较以往长,诱因不明显,而且还伴有短时间的胸闷,气短症状,家里人给其服用救心丸来解决此症状,但疗效不好,去大医院做全面的检查上述症状是由冠状动脉粥样硬化引起的。
服用本实施例4所得冲剂,每次一袋,每天3次,温开水冲服,10天一个疗程。服用10天,胸闷、心绞痛明显减轻,恶心、呕吐症状消失,纳量增,精神可,服用20天,心电图示冠状动脉供血明显改善,继服3个月,患者痊愈。
实施例5治疗冠状动脉粥样硬化的冲剂,主要由下列原料药制备而成,均为重量份(每份取20g):瓜蒌7.5,胜红蓟9,桂枝8,沙棘5,薤白10,桑皮4.5,丹参7,淡菜7,百部3.5,半夏10,猪苓9,泽泻7,五灵脂6。
上述治疗冠状动脉粥样硬化的冲剂的制备方法,步骤是:
(1)将整理好的原料药混合煎汁,共煎三次,每次待水沸后,再煎1.2小时,过滤取汁,药汁合并,用薄膜蒸发至每毫升含生药1-3克,加入一倍重量的乙醇(95%)边加边搅拌,沉淀20小时后过滤;
(2)滤液用薄膜蒸发至每毫升药液相当4.5克生药,加入冷水稀释成每毫升含生药1-3克,沉淀15小时后过滤;
(3)滤液用薄膜蒸发至浸膏状,浓缩液比重控制为1.05-1.2:1,放冷至80℃以下称总固体量;
(4)加总固体量3.5倍重量的白砂糖,0.9倍重量的糊精,用乙醇(65%),调节干湿度,用颗粒机制成颗粒,包装。
试验例1实施例5所得治疗治疗冠状动脉粥样硬化冲剂的临床应用:2010年6月-2013年12月,在4所医院筛选150例患者,其中女性100例,男性50例,年龄最大的72岁,最小年龄38岁,平均年龄55.2岁。试验之前2周,对该人群进行连续观察,记录症状及变化,随机分为两组,实验组及对照组,实验组服用实施例5所得产品,对照组服用其它药品(美托洛尔、利多卡因、去甲肾上腺素等常规药品)。使用方法为:每次一袋,每天3次,温开水冲服,10天一个疗程。疗效情况判定标准:治愈:服用本品一个疗程,心电图示冠状动脉供血明显改善,不适症状消失,精力及体力明显增强;有效:服用本品一个疗程,心电图示慢性冠状动脉供血改善,不适症状减轻或部分消失,精力及体力增强;无效:服用本品一个疗程,不适症状无变化。结果如表1所示。
表1:服用实施例5产品38-72岁冠状动脉粥样硬化患者治疗结果
表1
治疗效果:治愈95例(95%),有效率98%。效果明显优于对照组。
服用期间自感症状及其体力精神变化如表2所示。
表2:
本发明选择瓜蒌、胜红蓟、桂枝、沙棘、薤白、桑皮、丹参等进行配伍,使得这些药物组合后产生协同作用,诸药合用,活血而能养阴,祛瘀而不伤正,开窍而兼益气,故可获得良好的治疗效果。服用10天,53%以上的感到有所好转,不适症状改善;服用20天,72%以上的感到有所好转,不适症状改善或消失,精神、体力增强;服用30天,97%以上的感到有所好转,不适症状改善或消失,精神、体力增强,冠状动脉造影显示动脉正常,部分患者自感痊愈。实验组中服用30天以上,有效率可达93%,而对照组仅为76%。本发明所述冲剂具有活血通经,散淤止痛功效,对治疗动脉粥样硬化与冠心病有特殊的疗效。
Claims (7)
1.治疗冠状动脉粥样硬化的冲剂,其特征是,主要由下列原料药制备而成,均为重量份:瓜蒌7,胜红蓟8,桂枝7,沙棘4,薤白9,桑皮4,丹参6,淡菜6,百部3,半夏9,猪苓8,泽泻6,五灵脂5。
2.根据权利要求1所述治疗冠状动脉粥样硬化的冲剂的制备方法,其特征是,步骤如下:
(1)将整理好的原料药混合煎汁,共煎三次,每次待水沸后,再煎0.8-1.4小时,过滤取汁,药汁合并,用薄膜蒸发至每毫升含生药1-3克,加入一倍重量的乙醇(95%)边加边搅拌,沉淀15-25小时后过滤;
(2)滤液用薄膜蒸发至每毫升药液相当4-5克生药,加入冷水稀释成每毫升含生药1-3克,沉淀8-24小时后过滤;
(3)滤液用薄膜蒸发至浸膏状,浓缩液比重控制为1.05-1.2:1,放冷至80℃以下称总固体量;
(4)加总固体量2-5倍重量的白砂糖,0.5-1.2倍重量的糊精(优选加入0.9倍重量的糊精),用乙醇(65%),调节干湿度,用颗粒机制成颗粒,包装。
3.根据权利要求2所述的制备方法,其特征是,步骤(1)再煎1-1.3小时(优选1.2小时)。
4.根据权利要求2所述的制备方法,其特征是,步骤(1)沉淀18-23小时后过滤(优选20小时)。
5.根据权利要求2所述的制备方法,其特征是,步骤(2)蒸发至每毫升药液相当生药4.2-4.8克(优选4.5克)。
6.根据权利要求2所述的制备方法,其特征是,步骤(2)沉淀13-18小时后过滤(优选15小时)。
7.根据权利要求2所述的制备方法,其特征是,步骤(4)加总固体量3-4倍重量的白砂糖(优选3.5倍)。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610164887.7A CN105687962A (zh) | 2014-03-07 | 2014-03-07 | 治疗冠状动脉粥样硬化的冲剂及制备方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410082159.2A CN103845670B (zh) | 2014-03-07 | 2014-03-07 | 治疗冠状动脉粥样硬化的冲剂及制备方法 |
CN201610164887.7A CN105687962A (zh) | 2014-03-07 | 2014-03-07 | 治疗冠状动脉粥样硬化的冲剂及制备方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410082159.2A Division CN103845670B (zh) | 2014-03-07 | 2014-03-07 | 治疗冠状动脉粥样硬化的冲剂及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105687962A true CN105687962A (zh) | 2016-06-22 |
Family
ID=50854074
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610164879.2A Withdrawn CN105687961A (zh) | 2014-03-07 | 2014-03-07 | 一种治疗冠状动脉粥样硬化冲剂的制备方法 |
CN201410082159.2A Expired - Fee Related CN103845670B (zh) | 2014-03-07 | 2014-03-07 | 治疗冠状动脉粥样硬化的冲剂及制备方法 |
CN201610164887.7A Withdrawn CN105687962A (zh) | 2014-03-07 | 2014-03-07 | 治疗冠状动脉粥样硬化的冲剂及制备方法 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610164879.2A Withdrawn CN105687961A (zh) | 2014-03-07 | 2014-03-07 | 一种治疗冠状动脉粥样硬化冲剂的制备方法 |
CN201410082159.2A Expired - Fee Related CN103845670B (zh) | 2014-03-07 | 2014-03-07 | 治疗冠状动脉粥样硬化的冲剂及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (3) | CN105687961A (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104435659A (zh) * | 2014-09-01 | 2015-03-25 | 周春美 | 治疗冠状动脉粥样硬化性心脏病心绞痛的中药片剂及其制备方法 |
CN104922504A (zh) * | 2015-05-29 | 2015-09-23 | 张慧玲 | 治疗动脉粥样硬化的醋饮及制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1679904A (zh) * | 2005-01-12 | 2005-10-12 | 王振球 | 一种治疗心力衰竭的中药 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102078510B (zh) * | 2011-01-24 | 2011-11-16 | 孙华清 | 治疗冠心病的中药组合物 |
-
2014
- 2014-03-07 CN CN201610164879.2A patent/CN105687961A/zh not_active Withdrawn
- 2014-03-07 CN CN201410082159.2A patent/CN103845670B/zh not_active Expired - Fee Related
- 2014-03-07 CN CN201610164887.7A patent/CN105687962A/zh not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1679904A (zh) * | 2005-01-12 | 2005-10-12 | 王振球 | 一种治疗心力衰竭的中药 |
Non-Patent Citations (2)
Title |
---|
余洪刚等: "温阳补心汤配合西药治疗慢性心力衰竭34例", 《陕西中医》 * |
苟奎斌: "我们对冲剂的改进", 《中国医院药学杂志》 * |
Also Published As
Publication number | Publication date |
---|---|
CN105687961A (zh) | 2016-06-22 |
CN103845670A (zh) | 2014-06-11 |
CN103845670B (zh) | 2016-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103919910B (zh) | 一种治疗冠心病的药物 | |
CN103893670B (zh) | 一种治疗心脑血管病的中药药丸 | |
CN104069446A (zh) | 一种治疗冠心病心绞痛的中药组合物 | |
CN103977092B (zh) | 一种治疗心肌梗塞、脑梗的药物组合物 | |
CN103393943B (zh) | 一种治疗脑梗塞后遗症的中药组合物 | |
CN102343049B (zh) | 一种治疗肝阳上亢型高血压病的中药胶囊 | |
CN105687962A (zh) | 治疗冠状动脉粥样硬化的冲剂及制备方法 | |
CN104825956A (zh) | 防治中风、康复筋骨关节的药 | |
CN105169078A (zh) | 一种治疗糖尿病的中药组合物 | |
CN104800772A (zh) | 一种治疗气郁型冠心病的中药组合物及应用 | |
CN104338052A (zh) | 治疗脑血栓的中药配方 | |
CN103845671B (zh) | 心力衰竭温阳益气散及制备方法 | |
CN106692858A (zh) | 一种治疗胎动不安的药物及其制备方法 | |
CN105194105A (zh) | 一种治疗心血不足型心律失常的中药 | |
CN105816763A (zh) | 治疗冠状动脉粥样硬化冲剂的制备方法 | |
CN104436060A (zh) | 一种护理治疗胆管细胞癌的中药配方及其制备方法 | |
CN104547999A (zh) | 产后发汗用油 | |
CN103933368B (zh) | 用于治疗产后便秘的药物组合物及其制备方法 | |
CN103860991B (zh) | 急性心衰补气安神冲剂及制备方法 | |
CN105194476A (zh) | 一种冠心病活血通络散 | |
CN105770646A (zh) | 治疗冠状动脉粥样硬化的冲剂 | |
CN105396013A (zh) | 心肌缺血温阳益气冲剂在制备治疗肺心病、心肌梗塞、心肌坏死、心绞痛的药物中的应用 | |
CN105031542A (zh) | 一种治疗病毒性心肌炎的中药汤剂及其制备方法 | |
CN105663950A (zh) | 一种心力衰竭温阳益气散及其制备方法 | |
CN105709144A (zh) | 一种心力衰竭温阳益气散 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 545000 the Guangxi Zhuang Autonomous Region road Liunan District Liuzhou City Lake in Hexi District 2 building 1-1001 Applicant after: Chen Xicheng Address before: 250014 Shandong Province, Lixia District of Ji'nan city jiangshuiquan Road No. 1 jichai nine dormitory 2 floor 1 unit 201 Applicant before: Chen Xicheng |
|
CB02 | Change of applicant information | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160622 |
|
WW01 | Invention patent application withdrawn after publication |